Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Mov Disord > Volume 17(4); 2024 > Article
Brief communication
Journey Through Autosomal-Recessive Spastic Ataxia of Charlevoix–Saguenay: Insights From a Case Series of Seven Patients–A Single-Center Study and Review of an Indian Cohort
Mit Ankur Raval1orcid, Vikram V Holla1corresp_iconorcid, Nitish Kamble1orcid, Gautham Arunachal2orcid, Babylakshmi Muthusamy3,4orcid, Jitender Saini5orcid, Ravi Yadav1orcid, Pramod Kumar Pal1orcid
Journal of Movement Disorders 2024;17(4):430-435.
DOI: https://doi.org/10.14802/jmd.24154
Published online: August 29, 2024

1Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, India

2Department of Human Genetics, National Institute of Mental Health and Neurosciences, Bengaluru, India

3Institute of Bioinformatics, International Technology Park, Bengaluru, India

4Department of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India

5Department of Neuroimaging and Interventional Radiology, National Institute of Mental Health and Neurosciences, Bengaluru, India

Corresponding author: Vikram V Holla, MD, DM Department of Neurology, National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru-560029, Karnataka, India / Tel: +91-80-26995966 / E-mail: vikramvholla@gmail.com
• Received: July 3, 2024   • Revised: August 21, 2024   • Accepted: August 29, 2024

Copyright © 2024 The Korean Movement Disorder Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 792 Views
  • 212 Download
  • Objective
    In this study, we describe the clinical and investigative profiles of 7 cases of autosomal-recessive spastic ataxia of Charlevoix–Saguenay (ARSACS).
  • Methods
    We performed a retrospective chart review of genetically proven cases of ARSACS from our database. Additionally, we reviewed the literature for reported cases of ARSACS from India.
  • Results
    All 7 patients experienced disease onset within the first decade of life. According to the available data, all patients had walking difficulty (7/7), spastic ataxia (7/7), classical neuroimaging findings (7/7), sensory‒motor demyelinating polyneuropathy (6/6), abnormal evoked potentials (5/5), and a thickened retinal nerve fiber layer (3/3). Exome sequencing revealed 8 unique pathogenic/likely pathogenic variants (6 novel) in the SACS gene. An additional 21 cases (18 families) of ARSACS that could be identified from India had similar clinical and investigational findings. The most common c.8793delA variant may have a founder effect.
  • Conclusion
    Our series adds to the previously reported cases of ARSACS from India and expands the genetic spectrum by adding 6 novel variants.
Autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS) was first discovered in 1978 in the Saguenay-LacSt-Jean region of northeastern Quebec [1]. Later, in 2000, the SACS gene was identified by Engert et al. [2] as being responsible for the disease. This condition has subsequently been detected in diverse geographical regions worldwide, including India. A majority of affected individuals develop slowly progressive ataxia within the first decade; this is accompanied by spasticity in childhood and neuropathy during adolescence [3-8]. In addition to these clinical findings, the classical findings of horizontal pontine striae with superior vermian atrophy on magnetic resonance imaging (MRI), demyelinating polyneuropathy on nerve conduction studies (NCSs) and a thickened retinal nerve fiber layer (RNFL) on optical coherence tomography (OCT) are helpful in achieving a diagnosis. The identification of biallelic pathogenic variants is confirmatory. Despite this condition having its onset in the first decade, ambulation is maintained in the majority of affected individuals until adulthood, and this condition has a relatively better prognosis when compared to other first-decade-onset spastic ataxia with peripheral neuropathy syndromes [3]. Our study aims to provide detailed clinical, electrophysiological, imaging and genetic profiles of genetically proven cases of ARSACS from a single center in India. In addition, we reviewed previously reported cases of ARSACS from India.
In this retrospective study from a tertiary neurology referral center in India, we screened our database for patients with genetically proven ARSACS. The available clinical, radiological, electrophysiological, and genetic data were documented and analyzed. The data was analyzed using descriptive statistics and presented as medians (ranges) or frequencies and percentages. The study was approved by the National Institute of Mental Health and Neurosciences Institute Ethics Committee (No. NIMH/DO/IEC [BS & NS DIV]/2022-23), and written informed consent was obtained from the patients for participation in the study, video recording and publication in print or online.
We identified 7 patients (4 males) with genetically proven ARSACS with a median age at onset of 5 years (3–7 years) and duration of illness of 20.5 years (10–35 years). The clinical, imaging, electrophysiological, genetic, treatment, and follow-up details are summarized in Supplementary Table 1 (in the online-only Data Supplement). The MRI findings of 6 patients are provided in Figure 1 and the clinical examination videos of 2 patients are provided as Supplementary Video 1 (in the online-only Data Supplement) (patient-2) and Supplementary Video 2 (in the online-only Data Supplement) (patient-4).
Clinical details
Walking difficulty (7/7) was the most common presenting symptom. Patients also experienced slurring of speech (2/7), abnormal posturing of the neck (1/7) and hands (2/7), leg weakness (1/7), and global developmental delay with intellectual disability (2/7). A positive family history of similar clinical findings and consanguineous parentage was noted in 2 and 5 patients, respectively.
All patients had cerebellar and pyramidal involvement. Ataxic dysarthria and appendicular ataxia were noted in all patients, and gait ataxia was noted in 5 patients. Gait was spastic-ataxic in 4 patients, ataxic in 1 patient and spastic in 2 patients. Additionally, cerebellar eye signs were noted in 6 patients (gaze evoked nystagmus: 7/7; dysmetric saccades: 4/7; broken pursuits: 3/7; and ill-sustained upbeat nystagmus: 1/7). All patients had bilateral lower limb (LL) spasticity. In addition, upper limb (UL) spasticity, distal UL hypotonia and distal LL hypotonia were noted in one patient each. Deep tendon reflexes were brisk in all patients, ankle jerk was present in 3 patients but was absent in the other 4 patients. The plantar response was extensor in all patients.
The classical retinal sign of ARSACS, hypermyelinated fibers radiating from the optic disc on fundus examination, was noted in four patients. Other neurological signs noted were cognitive impairment (1 patient), abnormal proprioceptive sensation in LL (2 patients), and dystonia (bilateral hand dystonia: 2 patients; cervical with left-hand dystonia: 1 patient).
Imaging and electrophysiology
All patients had classical neuroimaging findings of perithalamic T2 hyperintensity, pontine transverse fiber hypointensity with bulky pons, and superior vermian and cerebellar atrophy (Figure 1). Spinal cord atrophy was noted in 6 patients. All 3 patients with peri-optic disc hypermyelinated nerve fibers had a thickened RNFL on OCT (Figure 2). Evoked potentials were abnormal in five patients, and NCS revealed LL predominant sensorimotor demyelinating polyneuropathy in all 6 patients who underwent the tests.
Genetic testing
Exome sequencing of all 7 patients revealed eight unique pathogenic or likely pathogenic variants (homozygous: 6 patients; compound heterozygous: 1 patient) in the SACS gene. Of the eight variants, two variants have been previously described (c.6000_6004del:p.Arg2002CysfsTer25 and c.10686_10689 delCTTT:p.Phe3562LeufsTer8), and the other six variants were novel (c.8240T>A:p.Il2747Asn, c.3810delT:p.Phe1270LeufsTer4, c.13531del:p.Glu4511AsnTer9, c.11356G>T:p.Glu3786Ter, c.13469A>C:p.Tyr4490Ser, and c.1908delG:p.Lys63SerfsTer15).
Treatment and follow-up
All patients were treated symptomatically with baclofen for spasticity. Amantadine was given to 2 patients for ataxia, and clonazepam was given to 1 patient for dystonia. In addition, all patients received physiotherapy and speech therapy. Follow-up data were available for 5 patients (range: 6–12 months), and four-fifths of the patients noted mild improvement in their symptoms with no new symptoms.
Review of the literature regarding patients with ARSACS from India
In addition to seven cases from this study, we identified an additional 21 (18 families) cases from 11 publications after removing duplicates (Supplementary Table 2 in the online-only Data Supplement). The age at onset ranged from 1–37 years, with a first-decade onset noted in approximately two-thirds of the patients (17/27 patients). A total of fifteen-seventeenths of the families for whom data were available belonged to the southern part of India. Walking difficulty was the most common presenting symptom. Spasticity with ataxia was noted in nearly all patients. Hypermyelinated nerve fibers radiating from the optic disc were observed in 8 patients, whereas another 8 patients were reported to have a normal fundus.
NCSs revealed demyelinating neuropathy in more than two-thirds of the patients (16/21 patients) and axonal neuropathy in the remaining patients. On MRI, pontine stripes were noted in all but three patients. Thickened RNFL on OCT was observed in 8 patients, and the data were not available for the remaining patients. In seven of these patients with OCT abnormalities, fundus examination also revealed peripapillary retinal streaks. Genetic testing details were available for 23 families (26 patients), which revealed pathogenic variants in a homozygous state in 18 families, a compound heterozygous state in four families and a heterozygous state in one family. In total, 21 unique variants were identified, of which the c.8793delA variant (5 patients, 5 families), the c.12851_12854del variant (3 patients, 2 families) and the c.10686_10689del variant (2 patients, 2 families) were the only three variants identified in more than one family. All patients harboring the c.8793delA variant were from Kerala. Truncating variants were the most frequent (17/21 variants), constituting 10 frameshift deletion variants, four stop-gain variants and three frameshift duplication variants. The remaining four were missense variants.
This study expands the genetic spectrum of ARSACS by reporting six novel variants and adds 7 cases to the literature with detailed descriptions of clinical and investigative findings. Overall, the findings of our study are in accordance with our current understanding of ARSACS [3-5]. In line with previous findings, our patients also had predominantly early-onset slowly progressive spastic-ataxic syndrome with demyelination-predominant polyneuropathy, thickened peri-optic disc RNFL, and horizontal pontine stria, among other classical radiological findings. Most of the patients experienced some mild improvement in response to symptomatic medications at the 6–12-month follow-up.
Clinical profile
ARSACS is usually a disease of first decade onset and can have developmental delays, especially motor delays, that eventually improve with age as milestones are attained slowly. Walking difficulty is one of the most common presenting symptoms [3]. In addition to ataxia, LL-predominant pyramidal signs are common and are observed in more than three-fourths of cases. However, with disease progression, neuropathy eventually results in the absence of pyramidal signs in LL. Even then, the extensor plantar response may persist, resulting in a phenotype akin to Friedreich’s ataxia (FA), with ataxia, neuropathy and an extensor plantar response. However, peri-optic retinal streaks or thickened peri-optic disc RNFL are observed in more than 50% of patients with ARSACS, and the absence of cardiac involvement and diabetes mellitus helps distinguish it from FA. Additionally, the early first decade of onset of ARSACS is usually too early for FA.
In addition to the usual progressive cerebellar ataxia, peripheral neuropathy, and spasticity in LLs, certain individuals with ARSACS may present with additional features, including hearing impairment, intellectual disability, myoclonic epilepsy, dystonia, dysphagia, and urinary dysfunction [9-12]. Patients may have features of long-standing neuropathy [3,13]. Four of our patients had mild focal or multifocal dystonia, which was previously reported in ARSACS but in fewer than 10% of cases [3,4,8]. Dysarthria is common and is observed in the majority of cases of varying severity, and patients can experience oculomotor abnormalities, mainly in the form of nystagmus. However, visual impairment, hearing impairment, dysphagia and dysphonia are rare. Some individuals may encounter challenges in school performance, occasionally attributed to mild intellectual disability; however, it is important to note that ARSACS is not associated with severe intellectual disability [14].
Investigations
Investigations such as MRI, OCT, and NCS can confirm the diagnosis or provide clues toward the possibility of ARSACS. The combination of horizontal pontine T2/FLAIR hypointense stripes (the tigroid pattern), superior vermian atrophy and bulky pons on brain magnetic resonance images often helps in differentiating ARSACS from other first-decade-onset ataxias [3,6]. The thickly myelinated transverse pontocerebellar tracts give rise to pontine striae and bulky pons findings. Other usually observed MRI brain findings are T2/FLAIR hyperintensity of the lateral pons and thalamus, a thickened middle cerebellar peduncle, thinning of the posterior mid-body callosum, parietal atrophy, arachnoid cysts and spinal cord atrophy [13].
OCT is another imaging modality that is useful in the diagnosis of ARSACS. Clinically, thickened peri-optic RNFLs appear as retinal streaks radiating from the optic disc, and on OCT, they appear as thickened peripapillary RNFLs [15]. A cutoff value of 119 μm for average peripapillary RNFL thickness was proposed, which has a sensitivity of 100% and specificity of 99.4% [16]. Fundoscopy can be abnormal in 70% of cases and can be normal despite having a thickened RNFL on OCT. RNFL thickness shares the common pathogenesis of aberrant thickening of nerve fibers, resulting in pontine striae on MRI [15].
Very few patients with early-onset ataxia can have demyelinating neuropathy, in contrast to the axonal predominance observed in many other causes. Demyelinating sensorimotor neuropathy is identified in the majority of ARSACS cases [3,17]. Evoked potentials also demonstrate a slowed conduction time in the form of dispersed and prolonged latency of motor, visual, evoked and somatosensory evoked potentials [7,13,17].
Genetic testing
ARSACS results from variants in the SACS gene situated on chromosome 13q12, which is responsible for encoding the 520-kDa protein sacsin [4]. This protein is expressed predominantly in Purkinje cells and plays a crucial role in regulating intermediate filament assembly and dynamics. Among the more than 700 pathogenic or likely pathogenic variants described, more than 90% are truncating variants (deletion/duplication/splice-site/stop-gain). Our study identified six novel variants (frameshift deletion: 3, stop gain: 1, missense: 2). Multiple studies have failed to identify any definite phenotype‒genotype correlations. A recent study demonstrated that the sacsin level was almost absent in patients with ARSACS irrespective of the underlying variant type. They also demonstrated that cotranslational ubiquitination and degradation of nascent mutant sacsin protein is a novel underlying mechanism in ARSACS instead of mRNA decay, defective translation, or faster posttranslational degradation [18].
ARSACS in India
Most of the cases reported from India are from southern India (Kerala, Karnataka, Andhra Pradesh, Tamil Nadu, and Telangana). However, the two large studies are from Kerala [13] and Karnataka, which can partially explain these findings. The overall findings were in line with those in Western literature. Notably, one variant, c.8793delA, was identified in five unrelated patients, but all 5 patients lived in the same state, Kerala [13,19,20]. None of these patients had apparent parental consanguinity, but four of them had a homozygous state, and two of them had a positive family history, suggesting a high carrier frequency in this region. Further studies are needed to explore the possibility of a common founder variant in this population.
In conclusion, our study expands the genotypic spectrum of ARSACS by reporting six novel disease-causing variants. Moreover, the clinical, radiological and electrophysiological findings are in line with the previous literature, substantiating that the syndrome as a whole is relatively uniform across geography.
The online-only Data Supplement is available with this article at https://doi.org/10.14802/jmd.24154.
Video 1.
Video of patient-2: The video reveals mild pes-cavus, hammer toes, ataxic speech, broken pursuit, nystagmus, dysmetric saccades, lowerlimb predominant appendicular ataxia and spastic ataxic gait.
Video 2.
Video of patient-4: The video reveals mild ataxic speech, nystagmus, lower-limb predominant appendicular ataxia, spastic ataxic gait and impaired tandem gait. In addition, the patient had flat feet visible while walking but appeared to have pes-cavus lying down.
Supplementary Table 1.
Demographic, clinical features, investigation findings and follow-up details of the cohort
jmd-24154-Supplementary-Table-1.pdf
Supplementary Table 2.
Clinical, radiological, electrophysiological and genetic details of patients with ARSACS reported from India
jmd-24154-Supplementary-Table-2.pdf

Conflicts of Interest

The authors have no financial conflicts of interest.

Funding Statement

Partially funded by Department of Biotechnology, Government of India for funded project (BT/PR26428/MED/12/783/2017).

Author Contributions

Conceptualization: Mit Ankur Raval, Vikram V Holla, Pramod Kumar Pal.

Data curation: Mit Ankur Raval, Vikram V Holla, Pramod Kumar Pal. Formal analysis: Mit Ankur Raval, Vikram V Holla. Funding acquisition: Nitish Kamble, Babylakshmi Muthusamy, Ravi Yadav, Pramod Kumar Pal. Investigation: all authors. Methodology: all authors. Project administration: Babylakshmi Muthusamy, Ravi Yadav, Pramod Kumar Pal. Resources: all authors. Supervision: Vikram V Holla, Nitish Kamble, Gautham Arunachal, Babylakshmi Muthusamy, Jitender Saini, Ravi Yadav, Pramod Kumar Pal. Validation: Vikram V Holla, Nitish Kamble, Gautham Arunachal, Babylakshmi Muthusamy, Jitender Saini, Ravi Yadav, Pramod Kumar Pal. Visualization: Vikram V Holla, Pramod Kumar Pal. Writing—original draft: Mit Ankur Raval. Writing—review & editing: Vikram V Holla, Nitish Kamble, Gautham Arunachal, Babylakshmi Muthusamy, Jitender Saini, Ravi Yadav, Pramod Kumar Pal.

None
Figure 1.
MRI brain and spinal cord of patient-1 to 5 and patient-7. T1 (C1), T2 (A1, A4, B1, B4, D1, D4, E1–E4, F1, and F4) and FLAIR (A2, A3, B2, B3, C2, C3, D2, D3, F2, and F3) sequences of MRI brain and spinal cord of patients demonstrating superior vermian atrophy, bulky pons, thin corpus callosum (A1, B1, C1, D1, E1, and F1), perithalamic T2/FLAIR hyperintensity (A2, B2, C2, D2, E2, and F2), T2/FLAIR pontine horizontal striae (A3, B3, C3, D3, E3, and F3), and spinal cord atrophy (A4, B4, D4, E4, and F4). FLAIR, fluid-attenuated inversion recovery; MRI, magnetic resonance imaging.
jmd-24154f1.jpg
Figure 2.
Representative fundus image and OCT image of patient-4. A: Fundoscopy shows radiating whitish streaks of nerve fibers from the optic disc. B: OCT demonstrates above normal thickness of the retinal nerve fiber layer (black line and purple color) in the peripapillary region in both eyes. OCT, optical coherence tomography.
jmd-24154f2.jpg
  • 1. Bouchard JP, Barbeau A, Bouchard R, Bouchard RW. Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Can J Neurol Sci 1978;5:61–69.ArticlePubMed
  • 2. Engert JC, Bérubé P, Mercier J, Doré C, Lepage P, Ge B, et al. ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet 2000;24:120–125.ArticlePubMedPDF
  • 3. Vermeer S, van de Warrenburg BP, Kamsteeg EJ, Brais B, Synofzik M. ARSACS. In: GeneReviews ® [Internet]. Seattle: University of Washington; 1993-2024 [accessed on 2024 Jun 24]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1255.
  • 4. Vermeer S, Meijer RP, Pijl BJ, Timmermans J, Cruysberg JR, Bos MM, et al. ARSACS in the Dutch population: a frequent cause of early-onset cerebellar ataxia. Neurogenetics 2008;9:207–214.ArticlePubMedPMCPDF
  • 5. Baets J, Deconinck T, Smets K, Goossens D, Van den Bergh P, Dahan K, et al. Mutations in SACS cause atypical and late-onset forms of ARSACS. Neurology 2010;75:1181–1188.ArticlePubMed
  • 6. Prodi E, Grisoli M, Panzeri M, Minati L, Fattori F, Erbetta A, et al. Supratentorial and pontine MRI abnormalities characterize recessive spastic ataxia of Charlevoix-Saguenay. A comprehensive study of an Italian series. Eur J Neurol 2013;20:138–146.PubMed
  • 7. Synofzik M, Soehn AS, Gburek-Augustat J, Schicks J, Karle KN, Schüle R, et al. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis 2013;8:41.PubMedPMC
  • 8. Pilliod J, Moutton S, Lavie J, Maurat E, Hubert C, Bellance N, et al. New practical definitions for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay. Ann Neurol 2015;78:871–886.PubMed
  • 9. Terracciano A, Casali C, Grieco GS, Orteschi D, Di Giandomenico S, Seminara L, et al. An inherited large-scale rearrangement in SACS associated with spastic ataxia and hearing loss. Neurogenetics 2009;10:151–155.ArticlePubMedPDF
  • 10. Ali Z, Klar J, Jameel M, Khan K, Fatima A, Raininko R, et al. Novel SACS mutations associated with intellectual disability, epilepsy and widespread supratentorial abnormalities. J Neurol Sci 2016;371:105–111.ArticlePubMed
  • 11. Nascimento FA, Canafoglia L, Aljaafari D, Muona M, Lehesjoki AE, Berkovic SF, et al. Progressive myoclonus epilepsy associated with SACS gene mutations. Neurol Genet 2016;2:e83.ArticlePubMedPMC
  • 12. Briand MM, Rodrigue X, Lessard I, Mathieu J, Brais B, Côté I, et al. Expanding the clinical description of autosomal recessive spastic ataxia of Charlevoix-Saguenay. J Neurol Sci 2019;400:39–41.ArticlePubMed
  • 13. Divya KP, Cherian A, Dhing HK, Kumar S, Thomas B, Faruq M. Widening the clinical, radiological and genetic spectrum of autosomal recessive ataxia of Charlevoix-Saguenay in Indian patients. Acta Neurol Belg 2024;124:475–484.ArticlePubMedPDF
  • 14. Verhoeven WM, Egger JI, Ahmed AI, Kremer BP, Vermeer S, van de Warrenburg BP. Cerebellar cognitive affective syndrome and autosomal recessive spastic ataxia of Charlevoix-Saguenay: a report of two male sibs. Psychopathology 2012;45:193–199.ArticlePubMedPDF
  • 15. Pablo LE, Garcia-Martin E, Gazulla J, Larrosa JM, Ferreras A, Santorelli FM, et al. Retinal nerve fiber hypertrophy in ataxia of Charlevoix-Saguenay patients. Mol Vis 2011;17:1871–1876.PubMedPMC
  • 16. Parkinson MH, Bartmann AP, Clayton LMS, Nethisinghe S, Pfundt R, Chapple JP, et al. Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay. Brain 2018;141:989–999.ArticlePubMed
  • 17. Gazulla J, Benavente I, Vela AC, Marín MA, Pablo LE, Tessa A, et al. New findings in the ataxia of Charlevoix-Saguenay. J Neurol 2012;259:869–878.ArticlePubMedPDF
  • 18. Longo F, De Ritis D, Miluzio A, Fraticelli D, Baets J, Scarlato M, et al. Assessment of sacsin turnover in patients with ARSACS: implications for molecular diagnosis and pathogenesis. Neurology 2021;97:e2315–e2327.PubMedPMC
  • 19. Sheetal S, Kumar SA, Byju P. SACS mutation-positive autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS) from Kerala. Ann Indian Acad Neurol 2020;23:374–376.ArticlePubMedPMC
  • 20. Sheetal S, Sasikumar AK, Tomy LG. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS) in three brothers of a family from Kerala. Ann Mov Disord 2021;4:149–152.Article

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Comments on this article

      JEE YOUNG LEE

      Congratulations on your publication! A beautiful collection of this rare disease in South Asia!

      October 03, 2024

      Add a comment
      Figure
      • 0
      • 1
      Journey Through Autosomal-Recessive Spastic Ataxia of Charlevoix–Saguenay: Insights From a Case Series of Seven Patients–A Single-Center Study and Review of an Indian Cohort
      Image Image
      Figure 1. MRI brain and spinal cord of patient-1 to 5 and patient-7. T1 (C1), T2 (A1, A4, B1, B4, D1, D4, E1–E4, F1, and F4) and FLAIR (A2, A3, B2, B3, C2, C3, D2, D3, F2, and F3) sequences of MRI brain and spinal cord of patients demonstrating superior vermian atrophy, bulky pons, thin corpus callosum (A1, B1, C1, D1, E1, and F1), perithalamic T2/FLAIR hyperintensity (A2, B2, C2, D2, E2, and F2), T2/FLAIR pontine horizontal striae (A3, B3, C3, D3, E3, and F3), and spinal cord atrophy (A4, B4, D4, E4, and F4). FLAIR, fluid-attenuated inversion recovery; MRI, magnetic resonance imaging.
      Figure 2. Representative fundus image and OCT image of patient-4. A: Fundoscopy shows radiating whitish streaks of nerve fibers from the optic disc. B: OCT demonstrates above normal thickness of the retinal nerve fiber layer (black line and purple color) in the peripapillary region in both eyes. OCT, optical coherence tomography.
      Journey Through Autosomal-Recessive Spastic Ataxia of Charlevoix–Saguenay: Insights From a Case Series of Seven Patients–A Single-Center Study and Review of an Indian Cohort

      JMD : Journal of Movement Disorders Twitter
      Close layer
      TOP